2561414-57-9

2561414-57-9 structure
2561414-57-9 structure
  • Name: GNF2133 hydrochloride
  • Chemical Name: GNF2133 hydrochloride
  • CAS Number: 2561414-57-9
  • Molecular Formula: C24H31ClN6O2
  • Molecular Weight: 470.99
  • Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK DYRK
  • Create Date: 2022-06-26 18:11:32
  • Modify Date: 2024-01-08 09:01:19
  • GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes[1].

Name GNF2133 hydrochloride
Description GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes[1].
Related Catalog
Target

DYRK1A:0.0062 μM (IC50)

GSK3β:>50 μM (IC50)

In Vivo GNF2133 hydrochloride (30 mg/kg; p.o.) shows good oral absorption with oral bioavailability of 22.3%[1]. GNF2133 hydrochloride (30 mg/kg; p.o.; once a day for 5 days) shows the ability to proliferate β-cells in vivo[1]. GNF2133 hydrochloride (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion in RIP-DTA mice[1]. Pharmacokinetic Parameters of GNF2133 hydrochloride in CD-1 mice[1]. plasma (iv) plasma (po) pancreas (po) CL (mL/min/kg) 23.5 Vss (L/kg) 11 AUC (h·nM) 3268 10974 144420 Cmax(nM) 1977 1675 13319 tmax<(h) 0.03 3.0 3.0 Clast(nM) 36.6 19 1324 t1/2<(h) 6.6 3.4 6.6 F (%) 22.3 CD-1 mice; 30 mg/kg; p.o.sup>[1]. Animal Model: CD-1 mice[1] Dosage: 30 mg/kg Administration: P.o. Result: Showed good oral absorption and moderate plasma exposure with oral bioavailability of 22.3%. Animal Model: Wistar Han rat[1] Dosage: 30 mg/kg (0.5% methylcellulose + Tween-80) Administration: P.o.; once a day for 5 days Result: Increased cyclin D1 levels and overall cell density, and increased in cell proliferation marker Ki67 and insulin. Animal Model: Diphtheria toxin A (RIP-DTA) mice[1] Dosage: 3, 10, 30 mg/kg (20 mg/kg doxycycline (Dox) for 5 days) Administration: P.o., once a day for 35 days Result: Significantly improves glucose disposal capacity and increased insulin secretion.
References

[1]. Liu YA, et al. Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133. J Med Chem. 2020 Mar 26;63(6):2958-2973.

Molecular Formula C24H31ClN6O2
Molecular Weight 470.99
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.